Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

A Record Year: A Look at the Biotech IPOs for Q4 2018

The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.

Read More »

Lilly’s Taltz superior to Humira in late-stage PsA study

Eli Lilly and Co. said the company’s psoriatic arthritis (PsA) drug Taltz was found to be more effective than the world’s best-selling prescription medicine, AbbVie Inc.’s Humira, in a late-stage study.

Read More »

Inflammatory bowel disease tied to heart attack risk

People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.

Read More »

J&J says its psoriasis drug superior to Novartis’ in study

Johnson & Johnson said the company’s drug Tremfya was more effective than Novartis AG’s rival medicine Cosentyx, and met the main goal of a late-stage study in adults with moderate-to-severe plaque psoriasis.

Read More »

Exclusive: Orchard CEO Touts Transformative Power of Gene Therapy Following ASH Data Presentation

Orchard Therapeutics is developing a suite of autologous ex-vivo lentiviral gene therapies to correct a rare autoimmune disorder.

Read More »

Janssen’s Stelara Demonstrates Sustained Efficacy in Improving Clinical Remission Rates in Patients with Moderate to Severe Crohn’s Disease Throughout Three Years

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates and shows the drug to be generally well-tolerated in patients with Crohn’s disease.

Read More »

With $50 Million in Upfront Money, Takeda and Enterome Double Down on Crohn’s Disease

Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders, France-based Enterome and Japan’s Takeda Pharmaceutical have entered into a second agreement, this time with a specific focus on Crohn’s disease.

Read More »

U.S. appeals court upholds ruling that canceled Teva Copaxone patents

A U.S. appeals court upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd. on the blockbuster multiple sclerosis drug Copaxone.

Read More »

Roche and Novartis Strengthen Their Presence in the MS Market

Roche company Genentech has released data from a long-term clinical trial of Ocrevus (ocrelizumab) in multiple sclerosis. The U.S. FDA and the European Medicines Agency accepted Novartis’ marketing applications for siponimod (BAF312) to treat secondary-progressive multiple sclerosis in adults.

Read More »

J&J’s Stelara succeeds in chronic bowel disease study

Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom